Form D · Biotechnology
Immunocore Holdings plc
Abingdon, Oxfordshire, X0 · CIK 0001671927
Offering snapshot reported Jul 28, 2022 · SEC filing
- Reported sold
- $140M Offering amount: $140M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 20, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 28, 2022 | Initial | $139,999,988 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-454089
Source: Form D, filed Jul 28, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Bell | Director |
| David Berman | Executive |
| Travis Coy | Director |
| Brian Di Donato | Executive |
| Roy Herbst | Director |
| Bahija Jallal | Director, Executive |
| Siddharth Kaul | Director |
| Robert Perez | Director |
| Kristine Peterson | Director |
| Peter Ratcliffe | Director |
| Tina St. Leger | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
92 Park Drive Milton Park
Abingdon, Oxfordshire, X0, OX14 4RY
Abingdon, Oxfordshire, X0, OX14 4RY